Dry powder inhalation of macromolecules using novel PEG-co-polyester microparticle carriers

• Published in: International journal of pharmaceutics Vol. 441; no. 1-2; pp. 611 - 619
• Main Authors: Tawfeek, Hesham M., Evans, Andrew R., Iftikhar, Abid, Mohammed, Afzal R., Shabir, Anjum, Somavarapu, Satyanarayana, Hutcheon, Gillian A., Saleem, Imran Y.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 30.01.2013
• Subjects: Administration, Inhalation; Animals; biodegradability; breathing; Bronchi - cytology; Bronchi - metabolism; chemical structure; chloroform; Chymotrypsin - administration & dosage; Chymotrypsin - pharmacology; deoxyribonuclease I; Deoxyribonuclease I - administration & dosage; Deoxyribonuclease I - pharmacology; dispersibility; Drug Carriers - chemistry; Drug Delivery Systems; Dry powder inhalation; Dry Powder Inhalers; Emulsions; encapsulation; Epithelial Cells - metabolism; ethylene glycol; Fourier transform infrared spectroscopy; glycerol; Humans; Macromolecules; Microparticles; Microspheres; mucins; Mucins - metabolism; nuclear magnetic resonance spectroscopy; Particle Size; Poloxamer - chemistry; Polyester polymer; Polyesters - chemistry; Polyethylene Glycols - chemistry; polymers; Pulmonary drug delivery; respiratory tract diseases; solvents; spray drying; Swine; Time Factors; Pulmonary drug delivery; Dry powder inhalation; Polyester polymer; Macromolecules; Microparticles

This study investigated optimizing the formulation parameters for encapsulation of a model mucinolytic enzyme, α-chymotrypsin (α-CH), within a novel polymer; poly(ethylene glycol)-co-poly(glycerol adipate-co-ω-pentadecalactone), PEG-co-(PGA-co-PDL) which were then applied to the formulation of DNase...